Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8+ T-cells infiltration in triple-negative breast cancer
暂无分享,去创建一个
K. Khanna | D. Sinha | M. Kalimutho | D. Mittal | S. Srihari | Purba Nag | Shagufta Shafique | P. Raninga | D. Nanayakkara | Kathryn L. Parsons
[1] S. Lakhani,et al. CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer , 2018, EMBO molecular medicine.
[2] E. Winer,et al. Phase II study of ruxolitinib, a selective JAK1/2 inhibitor, in patients with metastatic triple-negative breast cancer , 2018, npj Breast Cancer.
[3] C. Pellet-Many,et al. Receptor Tyrosine Kinase Ubiquitination and De-Ubiquitination in Signal Transduction and Receptor Trafficking , 2018, Cells.
[4] K. Pietras,et al. The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence , 2018, Breast Cancer Research and Treatment.
[5] D. Fremont,et al. Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor , 2017, Cell.
[6] H. Clevers,et al. Cancer stem cells revisited , 2017, Nature Medicine.
[7] Franco Locatelli,et al. Imatinib and Nilotinib Off-Target Effects on Human NK Cells, Monocytes, and M2 Macrophages , 2017, The Journal of Immunology.
[8] L. Qu,et al. At the crossroads of cancer stem cells and targeted therapy resistance. , 2017, Cancer letters.
[9] M. Ragan,et al. The metastasis suppressor RARRES3 as an endogenous inhibitor of the immunoproteasome expression in breast cancer cells , 2017, Scientific Reports.
[10] C. Gong,et al. Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer* , 2016, The Journal of Biological Chemistry.
[11] L. Helman,et al. The Role of PDGFR-β Activation in Acquired Resistance to IGF-1R Blockade in Preclinical Models of Rhabdomyosarcoma1 , 2016, Translational oncology.
[12] Deborah S. Barkauskas,et al. Adenosine 2B Receptor Expression on Cancer Cells Promotes Metastasis. , 2016, Cancer research.
[13] N. Hynes,et al. Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models , 2016, Nature Communications.
[14] R. Yelensky,et al. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence , 2016, Science Translational Medicine.
[15] M. Belvin,et al. MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. , 2016, Immunity.
[16] Dhaval Patel,et al. Understanding the functional impact of copy number alterations in breast cancer using a network modeling approach. , 2016, Molecular bioSystems.
[17] I. Fernández,et al. Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting , 2016, Clinical Medicine Insights. Oncology.
[18] Sriganesh Srihari,et al. Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. , 2015, Trends in pharmacological sciences.
[19] Jong-In Park,et al. MEK1/2 Inhibitors: Molecular Activity and Resistance Mechanisms. , 2015, Seminars in oncology.
[20] T. Kondo,et al. AG490, a Jak2 inhibitor, suppressed the progression of murine ovarian cancer. , 2015, European journal of pharmacology.
[21] H. Sasano,et al. Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study , 2015, Breast Cancer Research.
[22] J. Koo,et al. Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer , 2015, Breast Cancer Research and Treatment.
[23] Yan Zhou,et al. Targeted Blockade of JAK/STAT3 Signaling Inhibits Ovarian Carcinoma Growth , 2015, Molecular Cancer Therapeutics.
[24] T. Nielsen,et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] Guojun Wu,et al. PDGFRα and β play critical roles in mediating Foxq1-driven breast cancer stemness and chemoresistance. , 2015, Cancer research.
[26] Ki-Chun Yoo,et al. Activation of KRAS promotes the mesenchymal features of basal-type breast cancer , 2015, Experimental & Molecular Medicine.
[27] F M Blows,et al. Association between CD8+ T-cell infiltration and breast cancer survival in 12,439 patients. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] P. Johnston,et al. ADAM17-dependent c-MET-STAT3 signaling mediates resistance to MEK inhibitors in KRAS mutant colorectal cancer. , 2014, Cell reports.
[29] E. Ranheim,et al. Combined MEK and JAK inhibition abrogates murine myeloproliferative neoplasm. , 2014, The Journal of clinical investigation.
[30] C. Gialeli,et al. PDGF/PDGFR signaling and targeting in cancer growth and progression: Focus on tumor microenvironment and cancer-associated fibroblasts. , 2014, Current pharmaceutical design.
[31] Justin M Balko,et al. Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer. , 2014, Discovery medicine.
[32] A. Vargas,et al. Kinome profiling reveals breast cancer heterogeneity and identifies targeted therapeutic opportunities for triple negative breast cancer , 2014, Oncotarget.
[33] R. Bernards,et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma , 2014, Nature.
[34] R. Yelensky,et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. , 2014, Cancer discovery.
[35] C. Heldin,et al. Targeting the PDGF signaling pathway in tumor treatment , 2013, Cell Communication and Signaling.
[36] P. Johnston,et al. Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.
[37] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[38] Michal Sheffer,et al. Pathway-based personalized analysis of cancer , 2013, Proceedings of the National Academy of Sciences.
[39] Ivan Babic,et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. , 2013, Cancer discovery.
[40] H. Brinkhaus,et al. JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. , 2012, Cancer cell.
[41] Sridhar Ramaswamy,et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells , 2012, Nucleic Acids Res..
[42] G. Mills,et al. Profiling of residual breast cancers after neoadjuvant chemotherapy identifies DUSP4 deficiency as a mechanism of drug resistance , 2012, Nature Medicine.
[43] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[44] Jian Jin,et al. Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer , 2012, Cell.
[45] Jeremy S Logue,et al. Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy. , 2012, Genes & development.
[46] S. Ramaswamy,et al. Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.
[47] G. Federici,et al. Platinum-(IV)-derivative satraplatin induced G2/M cell cycle perturbation via p53-p21waf1/cip1-independent pathway in human colorectal cancer cells , 2011, Acta Pharmacologica Sinica.
[48] Mithat Gönen,et al. The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. , 2011, The Journal of clinical investigation.
[49] Z. Szallasi,et al. An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.
[50] E. Alba,et al. Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer , 2010, BMC Cancer.
[51] L. Ellis,et al. Resistance to Targeted Therapies: Refining Anticancer Therapy in the Era of Molecular Oncology , 2009, Clinical Cancer Research.
[52] Wei Zhou,et al. In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models , 2009, Clinical Cancer Research.
[53] J. Bergh,et al. Prognostic significance of stromal platelet-derived growth factor beta-receptor expression in human breast cancer. , 2009, The American journal of pathology.
[54] A. Richardson,et al. Reciprocal Effects of STAT5 and STAT3 in Breast Cancer , 2009, Molecular Cancer Research.
[55] Johanna Andrae,et al. Role of platelet-derived growth factors in physiology and medicine. , 2008, Genes & development.
[56] M. Rojewski,et al. Nilotinib hampers the proliferation and function of CD8+ T lymphocytes through inhibition of T cell receptor signalling , 2008, Journal of cellular and molecular medicine.
[57] C. Cordon-Cardo,et al. Autocrine PDGFR signaling promotes mammary cancer metastasis. , 2006, The Journal of clinical investigation.
[58] J. Soulier,et al. Imatinib mesylate minimally affects bcr‐abl+ and normal monocyte‐derived dendritic cells but strongly inhibits T cell expansion despite reciprocal dendritic cell‐T cell activation , 2006, Journal of leukocyte biology.
[59] C. Restall,et al. Genomic analysis of a spontaneous model of breast cancer metastasis to bone reveals a role for the extracellular matrix. , 2005, Molecular cancer research : MCR.
[60] Zhixiang Wang,et al. Platelet-derived Growth Factor Receptor-mediated Signal Transduction from Endosomes* , 2004, Journal of Biological Chemistry.
[61] Jayanta Debnath,et al. Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. , 2003, Methods.
[62] B. Barre,et al. Opposite Regulation of Myc and p21 waf1 Transcription by STAT3 Proteins* , 2003, The Journal of Biological Chemistry.
[63] T. Yeatman,et al. Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[64] B. Druker,et al. The tyrosine kinase regulator Cbl enhances the ubiquitination and degradation of the platelet-derived growth factor receptor alpha. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[65] S. Ōmura,et al. Degradation Process of Ligand-stimulated Platelet-derived Growth Factor β -Receptor Involves Ubiquitin-Proteasome Proteolytic Pathway * , 1995, The Journal of Biological Chemistry.
[66] Mei Wang,et al. PDGF signaling in cancer progression , 2017 .
[67] Carsten Denkert,et al. Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[68] John D. Watson,et al. Promoter-binding and repression of PDGFRB by c-Myc are separable activities. , 2004, Nucleic acids research.